Overdiagnosis, Overtreatment or Oversurveillance of Melanoma: Is There a Way Out?

Welch HG, Mazer BL, Adamson AS. The Rapid Rise in Cutaneous Melanoma Diagnoses. N Engl J Med. 2021 Jan 7;384(1):72-79. doi: 10.1056/NEJMsb2019760. PMID: 33406334.

Breslow, Alexander (1970). "Thickness, Cross-Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma". Annals of Surgery. 172 (5): 902–8).

Who's More Likely to Develop a Second Primary Melanoma? Roxanne Nelson, RN, BSN; Medscape. November 30, 2022. https://www.medscape.com/viewarticle/984768

Olsen CM, Pandeya N, Dusingize JC, et al. Risk Factors Associated With First and Second Primary Melanomas in a High-Incidence Population. JAMA Dermatol. 2023;159(1):37–46. doi:10.1001/jamadermatol.2022.4975

Win Myint, TT, Selak, V, Elwood, M. The risk of subsequent invasive melanoma after a primary in situ or invasive melanoma in a high incidence country (New Zealand). Skin Health Dis. 2023; 3( 2):e116. https://doi.org/10.1002/ski2.116).

Marushchak O, Hazan E, Kriegel DA. Analyzing Controversies in Management and Surveillance of Early-Stage Melanoma. Oncol Ther. 2020 Dec;8(2):191-196. doi: 10.1007/s40487-020-00130-4. Epub 2020 Sep 15. PMID: 32930972; PMCID: PMC7683668.).

Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M. A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol. 2013 Sep;6(9):18-26. PMID: 24062870; PMCID: PMC3780800.

Ibrahim LS, Venables ZC, Levell NJ. The impact of COVID-19 on dermatology outpatient services in England in 2020. Clin Exp Dermatol. 2021 Mar;46(2):377-378. doi: 10.1111/ced.14547. Epub 2021 Jan 11. PMID: 33368434; PMCID: PMC9213926).

Jeremić J, Suđecki B, Radenović K, Mihaljević J, Radosavljević I, Jovanović M, Milić N, Pavlović V, Brašanac D, Jović M. Impact of the COVID-19 Pandemic on Melanoma Diagnosis: Increased Breslow Thickness in Primary Melanomas-A Single Center Experience. Int J Environ Res Public Health. 2022 Dec 14;19(24):16806. doi: 10.3390/ijerph192416806. PMID: 36554683; PMCID: PMC9779520.

Giulio Gualdi, Annamaria Porreca, Giuseppe Fabrizio Amoruso, Laura Atzori, Piergiacomo Calzavara-Pinton, Michele De Tursi, Andrea Di Buduo, Pietro Di Marino, Gabriella Fabroncini, Fabrizio Fantini, Maria Concetta Fargnoli, Gaetano Giannotta, Francesco Lacarruba, Andrea Lotesoriere, Martina Merli, Giuseppe Micali, Andrea Paradisi, Mario Puviani, Pietro Quaglino, Franco Rongioletti, Marco Rubatto, Paolo Sbano, Massimiliano Scalvenzi, Simone Soglia, Laura Sollima, Alessia Villani, Marta Di Nicola, Paolo Amerio, The Effect of the COVID-19 Lockdown on Melanoma Diagnosis in Italy, Clinics in Dermatology, Volume 39, Issue 5, 2021, Pages 911-919, ISSN 0738-081X,

https://doi.org/10.1016/j.clindermatol.2021.05.015.

Ackermann DM, Dieng M, Medcalf E, Jenkins MC, van Kemenade CH, Janda M, Turner RM, Cust AE, Morton RL, Irwig L, Guitera P, Soyer HP, Mar V, Hersch JK, Low D, Low C, Saw RPM, Scolyer RA, Drabarek D, Espinoza D, Azzi A, Lilleyman AM, Smit AK, Murchie P, Thompson JF, Bell KJL. Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial. JAMA Dermatol. 2022 Jan 1;158(1):33-42. doi: 10.1001/jamadermatol.2021.4704. Erratum in: JAMA Dermatol. 2022 Apr 27;: Erratum in: JAMA Dermatol. 2022 Jun 1;158(6):706. PMID: 34817543; PMCID: PMC8771298

Ideal settings, duration and frequency of follow-up for patients with melanoma. Cancer Council Australia. 2019. Available from: https://wiki.cancer.org.au/australia/Clinical_question:What_is_the_ideal_setting,_duration_and_frequency_of_follow-up_for_melanoma_patients%3F (Accessed Aug, 2022).

Adamson AS. The USPSTF I Statement on Skin Cancer Screening Not a Disappointment but an Opportunity. JAMA Dermatol. 2023;159(6):579-581. doi:10.1001/jamadermatol.2023.0706).